Clinical Case Reports (Jul 2023)
A case of high‐risk AML in a patient with advanced systemic mastocytosis
- Manlio Fazio,
- Calogero Vetro,
- Uroš Markovic,
- Andrea Duminuco,
- Marina Parisi,
- Cinzia Maugeri,
- Elisa Mauro,
- Nunziatina Laura Parrinello,
- Fabio Stagno,
- Loredana Villari,
- Anna Maria Triolo,
- Stefania Stella,
- Giuseppe A. Palumbo,
- Francesco Di Raimondo,
- Alessandra Romano,
- Roberta Zanotti
Affiliations
- Manlio Fazio
- Post Graduation School of Hematology University of Catania, A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Calogero Vetro
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Uroš Markovic
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Andrea Duminuco
- Post Graduation School of Hematology University of Catania, A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Marina Parisi
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Cinzia Maugeri
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Elisa Mauro
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Nunziatina Laura Parrinello
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Fabio Stagno
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Loredana Villari
- Department of Pathology A.O.U. Policlinico di Catania Catania Italy
- Anna Maria Triolo
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Stefania Stella
- Center of Experimental Oncology and Hematology A.O.U. Policlinico “G. Rodolico‐San Marco” Catania Italy
- Giuseppe A. Palumbo
- Post Graduation School of Hematology University of Catania, A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Francesco Di Raimondo
- Division of Hematology A.O.U. Policlinico “G.Rodolico‐San Marco” Catania Italy
- Alessandra Romano
- Dipartimento di specialità Medico‐Chirurgiche, CHIRMED, sezione di Ematologia Università degli Studi di Catania Catania Italy
- Roberta Zanotti
- Department of Medicine, Hematology Unit Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy
- DOI
- https://doi.org/10.1002/ccr3.7134
- Journal volume & issue
-
Vol. 11,
no. 7
pp. n/a – n/a
Abstract
Abstract Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine–venetoclax–midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.
Keywords
- advanced systemic mastocytosis (AdvSM)
- cladribine
- concurrent hematologic disease
- decitabine–venetoclax (DEC‐VEN)
- HAM regimen
- refractory acute myeloid leukemia (R‐AML)
